ImmuCell Corporation
ICCC
$5.07
-$0.20-3.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.75M | 6.01M | 5.47M | 7.26M | 5.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.75M | 6.01M | 5.47M | 7.26M | 5.10M |
| Cost of Revenue | 4.51M | 4.43M | 4.24M | 4.96M | 3.31M |
| Gross Profit | 3.24M | 1.58M | 1.23M | 2.30M | 1.78M |
| SG&A Expenses | 1.39M | 1.37M | 1.59M | 1.33M | 1.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.72M | 6.59M | 6.86M | 7.56M | 5.57M |
| Operating Income | 1.03M | -574.90K | -1.39M | -300.10K | -476.50K |
| Income Before Tax | 520.60K | -700.40K | -1.53M | -436.50K | -1.14M |
| Income Tax Expenses | 6.00K | 1.30K | 1.30K | 1.30K | 1.30K |
| Earnings from Continuing Operations | 514.60K | -701.70K | -1.53M | -437.90K | -1.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 514.60K | -701.70K | -1.53M | -437.90K | -1.14M |
| EBIT | 1.03M | -574.90K | -1.39M | -300.10K | -476.50K |
| EBITDA | 1.70M | 100.20K | -715.60K | 367.20K | 198.40K |
| EPS Basic | 0.06 | -0.09 | -0.20 | -0.06 | -0.15 |
| Normalized Basic EPS | 0.06 | -0.05 | -0.12 | -0.04 | -0.05 |
| EPS Diluted | 0.06 | -0.09 | -0.20 | -0.06 | -0.15 |
| Normalized Diluted EPS | 0.06 | -0.05 | -0.12 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 8.94M | 8.16M | 7.81M | 7.75M | 7.75M |
| Average Diluted Shares Outstanding | 8.94M | 8.16M | 7.81M | 7.75M | 7.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |